Background
==========

Probiotics are beneficial bacteria that can improve the micro-ecological balance of the host \[[@b1-medscimonit-23-4175]\]. Most probiotic bacteria belong to the genera *Lactobacillus* or *Bifidobacterium* and these bacteria are commonly added to probiotic drinks or yogurt products. Recent studies have shown that probiotics play a positive role in oral health \[[@b2-medscimonit-23-4175]\], and can affect the oral micro-ecology by changing the protein composition of dental plaque \[[@b2-medscimonit-23-4175]\]. This has stimulated research to study the anti-caries effect of probiotics.

The use of fluoride products and xylitol chewing gum has greatly reduced the prevalence of dental caries in children \[[@b3-medscimonit-23-4175],[@b4-medscimonit-23-4175]\]. However, the use of these products can result in the generation of fluoride resistant bacteria \[[@b5-medscimonit-23-4175]\], and the ingestion of xylitol chewing gum may be lethal for children \[[@b6-medscimonit-23-4175]\]. In China, 76.6% of children at the age of five suffer from dental caries \[[@b7-medscimonit-23-4175]\], therefore, safe and effective methods for the prevention of caries needs to be explored. As probiotics can produce different antibacterial compounds \[[@b8-medscimonit-23-4175]\], improve the oral microbial ecology, and rarely cause infections in humans, these organisms represent a safe and promising way to control caries.

Many studies have shown that caries are caused by ecological imbalance in the oral cavity \[[@b9-medscimonit-23-4175]\]. When caries-related bacteria increase and beneficial bacteria are reduced, the dental plaque can be transformed from non-cariogenic plaque to cariogenic plaque. Thus, the control of caries should be aimed at maintaining effective ecological balance of the oral flora. Cariostatic agents should not just have antibacterial activity against *Streptococcus mutans* (MS) and lactobacilli, but also affect the aerobes and anaerobes present in dental plaque. MS are one of the most important cariogenic bacteria and various *in vitro* studies have shown that *Lactobacillus rhamnosus* and *L. paracasei* can reduce the quantity of MS significantly \[[@b10-medscimonit-23-4175]\]. However, as with most probiotics research, the interpretation generally focuses solely on the levels of standard MS, while there are great different between the standard strains and clinical strains. Therefore, in this study we extracted dental plaque from children with active caries and mixed these organisms with probiotic lactobacilli, calculating the number of MS, oral *Streptococcus* (OS) and *Lactobacillus* (LB) in biofilms.

Our previous study has shown that five probiotic lactobacilli strains were able to inhibit growth and biofilm formation of MS, likely through the production of an acid environment, bacteriocin-like polypeptides or both \[[@b11-medscimonit-23-4175]\]. Here we compared the effect of four common commercial probiotic LB on clinically isolated MS strains and mixed biofilms from children with active caries to explore the practical value of probiotics in caries prevention.

Material and Methods
====================

Identification of MS from saliva of children with active caries
---------------------------------------------------------------

Experienced dentists in the Affiliated Hospital of Stomatology of Zhejiang University examined the children's oral health according to the International Caries Detection and Assessment System (ICDAS) standards. A total of 20 children with active caries (10 females, 10 males; range: 3--5 year of age) were asked to participate in the study after signing an informed consent form by their parents. The inclusion criteria were: DMFS ≥6, no antibiotic treatment in the past three months, good oral hygiene, and no systemic disease or abnormal tooth structures. The project was approved by the Ethics Committee of the Department of Conservative Dentistry and Periodontics, Affiliated Hospital of Stomatology, College of Medicine, Zhejiang University. All parents of the volunteers provided written informed consent.

Unstimulated whole saliva (1 mL) was collected from the children before a meal. Subgingival plaque was removed from the tooth with a sterile curette. All samples were sent to a microbiology laboratory and cultured within 2 hours.

The saliva specimens were vortexed for 1 minute, serially diluted with PBS buffer, and 50 μL of diluted saliva was cultured on mitis salivarius bacitracin agar (MSB) at 37°C in a microaerophilic atmosphere (5% O~2~, 10% CO~2~ and 85% N~2~) for 24 hours for MS. MS were verified by Gram-staining and their species identity was confirmed by using an automated mass spectrometry microbial identification system (Vitek, BioMérieux, France). After identification, the MS strains were purified on MSB again and were kept frozen at −80°C until used.

Interference test of the MS stains from saliva with four probiotic LB strains
-----------------------------------------------------------------------------

Four probiotic LB strains were used in this study (*L. casei* Shirota, *L. casei* LC01, *L. plantarum* ST-III, and *L. paracasei* LPC37). The LB were grown in DeMan Rogosa Sharpe agar (MRS) (Oxoid, UK) under microaerophilic conditions at 37°C for 48 hours. The isolated MS were cultured in brain heart infusion (BHI) medium (Oxoid, UK). After incubation, the concentrations of the LB and MS cultures were adjusted with VITEK Densichek (BioMérieux, France) to match the McFarland 0.5 standard (1.5×10^8^ CFU/mL) in PBS. Finally, 50 μL of the MS and LB cultures were combined with 2 mL BHI broth and incubated under microaerophilic conditions at 37°C for 24 hours. The *S. aureus* ATCC 25923 culture was used as the negative control, while 50 μL PBS was served as blank control.

After incubation, the suspensions were vortexed for one minute and serially diluted to 10^−3^. Then 100 μL of the suspension was plated on MSB and incubated under microaerophilic conditions at 37°C for 24 hours, after which the number of cells was counted. The inhibition rate was calculated according to the following formula:
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where A and B represent the colony number of experimental group and negative control respectively.

Interference test of the biofilm of dental plaque with four probiotic LB strains
--------------------------------------------------------------------------------

In this study, the dental plaque of each patient was extracted to carry out the biofilm experiment. The dental plaque collected from children with active caries were first cultured in BHI broth at 37°C under microaerophilic conditions for 24 hours, then the concentration of the mixed bacteria was adjusted to 1.5×10^8^ CFU/mL. Biofilm formation was conducted according to the method of Bueno-Silva B et al. \[[@b12-medscimonit-23-4175]\]. Each well in six-well plates was filled with 2 mL of BHI broth supplemented with 1% sucrose, and a piece of sterile hydroxyapatite (HA) was added to each well. 20 μL of the mixed bacterial suspension was added to each well along with 20 μL of LB suspension (1.5×10^8^ CFU/mL). As a control, 20 μL PBS was used. All six-well plates were incubated under microaerophilic conditions at 37°C for 24 hours.

The analyze of biofilm formation on HA from dental plaque by Quantitative real-time polymerase chain reaction
-------------------------------------------------------------------------------------------------------------

During the 24 hours of biofilm formation, the pH of the biofilms was measured every three hours. After incubation, the HA pieces were put in 1 mL of PBS buffer and vortexed for 90 seconds, then the culture was diluted in PBS to 10^−3^. Finally bacterial RNA from 100 uL of the suspension was prepared and analyzed by previously described methods \[[@b13-medscimonit-23-4175]\]. The qPCR primers used in this study are shown in [Table 1](#t1-medscimonit-23-4175){ref-type="table"}. Real time PCR was performed in triplicate in a 10 μL reaction volume containing 1×SYBR Green Master Mix (DBI, China), 100 nM specific primer and 50 ng template DNA on an ABI PRISM 7900HT system (Applied Biosystems Inc, USA) in 384-well PCR plates.

Statistical methods
-------------------

The data were analyzed with SPSS 14.0 software for Windows and data comparisons were performed with Dunnett's two-sided t-test. A *p*-value \<0.05 was considered as statistically significant.

Results
=======

Growth inhibition of MS
-----------------------

A total of 12 *S. mutans* strains were isolated from 20 children with active caries, then they were analyzed to determine if four strains of *Lactobacillus* possessed potential inhibitory effects on the growth of MS. *L. casei Shirota*, *L. casei LC01*, *L. plantarum* ST-III, and *L. paracasei LPC37*; all had a strong inhibitory effect on the majority of the MS isolated from the children with active caries and the inhibition rate reached approximately 70--90%. (*p*\<0.05; [Tables 2](#t2-medscimonit-23-4175){ref-type="table"}[](#t3-medscimonit-23-4175){ref-type="table"}[](#t4-medscimonit-23-4175){ref-type="table"}--[5](#t5-medscimonit-23-4175){ref-type="table"}).

Co-culture with lactobacilli influences different bacteria in biofilm
---------------------------------------------------------------------

The real-time PCR of the biofilm showed that *L. casei* Shirota, *L. casei* LC01, *L. plantarum* ST-III, *L. paracasei* LPC37 significantly reduced the numbers of MS, *Streptococcus spp*, *S. sanguinis* and total bacteria in the mixed biofilm cultures compared with the control group (*p*\<0.05; [Figure 1](#f1-medscimonit-23-4175){ref-type="fig"}). In the presence of the four *Lactobacillus* strains, the count of *S. sobrinus*, *S. salvarius*, *Porphorymonas gingivalis*, *S. oralis,* and *Actinomyces naeslundii* in the multispecies biofilms showed no significant difference compared with the control group (*p*\>0.05; [Figure 1](#f1-medscimonit-23-4175){ref-type="fig"}). The *L. casei* Shirota and *L. paracasei* LPC37 appeared to increase the total count of *S. gordonii* in the mixed biofilm (*p*\<0.05; [Figure 1](#f1-medscimonit-23-4175){ref-type="fig"}).

Discussion
==========

Our current *in vitro* study results suggest that probiotic lactobacilli have an effect on the growth and inhibition of at least four out of 12 MS isolated from children with active caries. This finding agrees with the results *in vivo* from the study that showed taking probiotic yogurt or beverages can significantly reduce the level MS in saliva \[[@b14-medscimonit-23-4175],[@b15-medscimonit-23-4175]\]. We selected clinical MS strain for our study, as different MS strains have different cariogenic potential \[[@b16-medscimonit-23-4175]\]. Understanding the effect of probiotics on clinically isolated MS strains has important significance for the prevention of caries in children.

LB are usually considered to be caries-related bacteria. However, in recent years, studies have shown that *L. plantarum* and *L. casei* can play a beneficial role in oral health rather than a cariogenic effect \[[@b17-medscimonit-23-4175]\]. The concentration of lactobacilli in probiotic products is usually between 1×10^8^/mL to 3×10^8^/mL and in our experiments the concentration of four LB strains were adjusted to 1.5×10^8^/mL. At this concentration, the four strains of LB had a significant inhibitory effect on MS, which is consistent with the *in vitro* results of Ahmed et al. \[[@b18-medscimonit-23-4175]\].

Antibacterial substances produced by probiotic lactobacilli include lactic acid, which can inhibit microbial growth by lowering the pH; hydrogen peroxide, which can inhibit bacterial DNA synthesis \[[@b19-medscimonit-23-4175]\]; and bacteriocins, which can destroy bacterial cell membranes to kill gram-positive bacteria. As MS is acid-tolerant and hydrogen peroxide production by LB is low, it is possible that the antibacterial substances in probiotics may be primarily bacteriocins or bacteriocin-like proteins. Studies have shown that *L. reuteri* and *L. plantarum* showed significant inhibitory effects on MS due to bacteriocin production \[[@b20-medscimonit-23-4175]\]. However, at present the antimicrobial mechanism of probiotic lactobacilli against MS is still not fully understood and requires further research.

Dental plaque is a biofilm structure which gradually sediments on the tooth surface. This structure contains a variety of bacteria that form a complex ecological environment in which streptococci and other caries-related microorganisms produce acid, which is the direct cause of tooth decay \[[@b21-medscimonit-23-4175]\]. In order to be effective at preventing caries, probiotics must have an inhibitory effect on *Streptococcus* species. Studies on intestinal microbes have confirmed that some lactic acid bacteria such as *L. rhamnosus* GG are able to have significant inhibition effects on pathogens \[[@b22-medscimonit-23-4175]\]. In our experiment, the numbers of *S. mutans*, *S. spp* and *S. sanguinis* cells in the mixed plaque biofilm decreased significantly when co-cultured with lactobacilli, indicating that probiotic lactobacilli may play a positive role in the prevention of caries.

It would be interesting to observe the antibacterial effect of probiotic lactobacilli on the growth of MS and multispecies biofilms isolated from children with active caries, however, the oral cavity is inhabited by a highly diverse and complex bacterial ecosystem that is difficult to simulate *in vitro* \[[@b23-medscimonit-23-4175]\]. Our results are *in vitro* results, therefore, to study *in vivo* the changes that occur in the oral flora after taking probiotics is still necessary for an understanding of the role of probiotic lactobacilli in oral health care. In future experiments, we plan to administer probiotic products to children and detect changes in the oral micro-ecology by using high-throughput sequencing technologies.

Conclusions
===========

The four probiotic strains tested here were able to inhibit the growth of MS and multispecies biofilms *in vitro*, had effects on the composition bacterial biofilms *in vitro*, and may have potential for use in the prevention of dental caries.
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![Viable *Streptococcus mutans* (Sm), *S. spp* (Spp), *S. sanguinis* (Ssag), *S. sobrinus* (Sso), *S. salvarius* (Sal), *Porphorymona gingivalis* (Pg), *S. oralis* (Soral), *S. gordonii* (Sgor) and *Actinomyces naeslundii* (An) in the biofilms (1) *Lactobacillus casei* Shirota, (2) *L. casei* LC01, (3) *L. plantarum* ST-III, (4) *L. paracasei* LPC37, and (C) control *(S. aureus)).* Data are expressed as the mean ±SD; \* *p*\<0.05; \*\* *p*\<0.01.](medscimonit-23-4175-g001){#f1-medscimonit-23-4175}

###### 

qPCR Primers used in this study.

  Species                        Sequence (5′ to 3′)            Target gene   Amplicon size(bp)
  ------------------------------ ------------------------------ ------------- -------------------
  *Streptococcus spp.*           F: GTACAGTTGCTTCAGGACGTATC     *tuf*         197
  R: ACGTTCGATTTCATCACGTTG                                                    
  *S. mutans*                    F: AGTGCCAAGACTGACGCTTT        *dexA*        141
  R: GGGCTGACTGCTTCTGGAGT                                                     
  *S. sobrinus*                  F: TGCCATCAACACTCTCTTGC        *gtfT*        162
  R: TGACCGAAACGAACCGATAC                                                     
  *S. gordonii*                  F: CGGATGATGCTAATCAAGTGACC     *gtfG*        177
  R: GTTAGCTGTTGGATTGGTTGCC                                                   
  *S. sanguinis*                 F: GTGTCATCAATTCCCAGAAAAG      *sodA*        104
  R: ATTATTGGCTGATGTGGAGTC                                                    
  *S. oralis*                    F: AAAGGCTGCTGTTGCTGAAG        *gtfR*        193
  R: GGGCAAGCGATCTTTCTTTG                                                     
  *S. salivarius*                F: CAGTGGGTTACTTTGGCTGTC       *gtfK*        133
  R: CCGACCGTAGTTGTTGAAGG                                                     
  *P. gingival*                  F: GGAAGAGAAGACCGTAGCACAAGGA   *rpoB*        143
  R: GAGTAGGCGAAACGTCCATCAGGTC                                                
  *A. naeslundii*                F: GTCTCTTCGCCCAGATCGAG        *ureC*        143
  R: GTTGGTGATGACGGTGTCG                                                      
  *Total Bacteria*               F: CCATGAAGTCGGAATCGCTAG       *16S rRNA*    89
  R: GCTTGACGGGCGGTGT                                                         

###### 

Inhibitory effects of *L. casei* Shirota on clinical isolated MS after 24 h (×10^8^ CFU/ml, means ±SD).

  Strains   *L. casei* Shirota                                                Blank control   Inhibition rate (%)
  --------- ----------------------------------------------------------------- --------------- ---------------------
  1         1.73±0.38                                                         6.24±1.37       72.27
  2         1.68±0.54[\*](#tfn1-medscimonit-23-4175){ref-type="table-fn"}     7.74±1.54       60.60
  3         3.65±1.24                                                         7.58±2.21       51.84
  4         2.41±0.87[\*](#tfn1-medscimonit-23-4175){ref-type="table-fn"}     8.01±2.45       69.91
  5         1.21±0.22[\*](#tfn1-medscimonit-23-4175){ref-type="table-fn"}     6.74±1.41       82.05
  6         1.74±0.41[\*](#tfn1-medscimonit-23-4175){ref-type="table-fn"}     6.66±0.74       73.87
  7         1.87±0.33[\*](#tfn1-medscimonit-23-4175){ref-type="table-fn"}     7.14±1.09       73.81
  8         4.41±1.77                                                         9.04±3.24       51.22
  9         1.01±0.24[\*\*](#tfn2-medscimonit-23-4175){ref-type="table-fn"}   7.11±0.87       85.79
  10        3.14±1.01                                                         8.14±1.99       61.42
  11        1.00±0.31[\*\*](#tfn2-medscimonit-23-4175){ref-type="table-fn"}   6.14±2.01       83.71
  12        1.66±0.65[\*](#tfn1-medscimonit-23-4175){ref-type="table-fn"}     8.45±2.35       80.36

P\<0.05;

P\<0.01.

###### 

Inhibitory effects of *L. casei* LC01 on clinical isolated MS after 24 h (×10^8^ CFU/ml, means ±SD).

  Strains   *L. casei* Shirota                                                Blank control   Inhibition rate (%)
  --------- ----------------------------------------------------------------- --------------- ---------------------
  1         2.45±0.78[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     6.66±1.35       63.21
  2         2.47±1.11[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     7.45±2.21       66.85
  3         3.47±1.56                                                         7.14±1.98       51.40
  4         1.45±0.87[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     7.87±1.54       81.57
  5         2.01±0.88[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     8.84±3.74       77.26
  6         1.35±0.65[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     7.75±2.20       82.58
  7         1.39±0.54[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     7.24±2.14       80.80
  8         1.22±0.41[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     6.87±1.11       82.24
  9         1.14±0.11[\*\*](#tfn4-medscimonit-23-4175){ref-type="table-fn"}   6.78±0.98       83.18
  10        3.33±1.42                                                         8.98±3.21       62.92
  11        1.36±0.77[\*\*](#tfn4-medscimonit-23-4175){ref-type="table-fn"}   7.77±2.39       82.49
  12        1.87±0.98[\*](#tfn3-medscimonit-23-4175){ref-type="table-fn"}     8.12±3.12       76.97

P\<0.05;

P\<0.01.

###### 

Inhibitory effects of *L. plantarum* ST-III on clinical isolated MS after 24 h (×10^8^ CFU/ml, means ±SD).

  Strains   *L. plantarum* ST-III                                             Blank control   Inhibition rate (%)
  --------- ----------------------------------------------------------------- --------------- ---------------------
  1         2.24±1.01[\*](#tfn5-medscimonit-23-4175){ref-type="table-fn"}     9.78±3.34       77.10
  2         2.54±0.87[\*](#tfn5-medscimonit-23-4175){ref-type="table-fn"}     8.89±2.21       71.43
  3         4.58±2.01                                                         10.45±4.53      56.17
  4         1.89±0.78[\*\*](#tfn6-medscimonit-23-4175){ref-type="table-fn"}   7.98±2.19       76.31
  5         2.11±0.99[\*](#tfn5-medscimonit-23-4175){ref-type="table-fn"}     8.98±3.01       76.50
  6         1.45±1.01[\*\*](#tfn6-medscimonit-23-4175){ref-type="table-fn"}   7.25±1.25       80.00
  7         3.54±1.87                                                         8.01±2.87       55.81
  8         2.78±0.98[\*](#tfn5-medscimonit-23-4175){ref-type="table-fn"}     9.01±3.78       69.15
  9         2.47±0.79[\*](#tfn5-medscimonit-23-4175){ref-type="table-fn"}     9.58±4.01       74.22
  10        2.22±1.11[\*](#tfn5-medscimonit-23-4175){ref-type="table-fn"}     8.88±3.21       75.00
  11        3.88±2.11                                                         10.14±4.12      61.73
  12        2.01±0.56[\*](#tfn5-medscimonit-23-4175){ref-type="table-fn"}     9.98±3.33       79.86

P\<0.05;

P\<0.01.

###### 

Inhibitory effects of *L. paracasei* LPC37 on clinical isolated MS after 24 h (×10^8^ CFU/ml, means ±SD).

  Strains   *L. paracasei* LPC37   Blank control   Inhibition rate (%)
  --------- ---------------------- --------------- ---------------------
  1         1.05±0.77              6.98±2.10       84.95
  2         2.25±1.21              9.27±2.26       75.73
  3         1.87±0.89              8.45±1.21       77.87
  4         2.38±1.24              8.45±1.39       71.83
  5         4.05±2.01              8.12±2.22       50.12
  6         1.49±0.78              6.98±0.79       78.65
  7         1.68±0.44              8.84±1.25       80.99
  8         3.98±1.59              7.58±0.88       47.49
  9         2.37±1.05              8.47±1.58       72.02
  10        2.39±1.02              7.87±2.01       69.45
  11        1.54±0.47              7.87±2.09       80.05
  12        2.07±1.24              9.01±3.21       77.03

P\<0.05;

P\<0.01.
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